Carboplatin Dosing Guidelines

Introduction to Carboplatin Dosing

The American Society of Clinical Oncology recommends using the Calvert formula to dose carboplatin, based on glomerular filtration rate (GFR) to achieve a target area under the curve (AUC), with a maximum GFR cap of 125 mL/min to prevent overdosing in patients with supranormal renal function 1, 2
The Calvert formula calculates the total dose in mg, which is a critical distinction from traditional chemotherapy dosing, and has been prospectively validated to accurately predict carboplatin exposure across a wide range of renal function (GFR 33-136 mL/min) 1

For patients with normal renal function, the target AUC of 4-6 mg/mL·min provides appropriate dosing, with AUC 5 mg/mL·min recommended as the standard target, while higher AUC values correlate with increased myelotoxicity, such as 16% experience grade 3-4 thrombocytopenia versus 33% at AUC 6-7 mg/mL·min 1, 2
The target AUC must be adjusted for combination chemotherapy regimens, as the formula measures drug exposure, not toxicity, and the maximum carboplatin dose should not exceed AUC (mg·min/mL) × 150 mL/min to prevent overdosing 1, 2

The GFR used in the Calvert formula should not exceed 125 mL/min, and for obese patients, dosing based on GFR is most reasonable because carboplatin clearance correlates with GFR, which correlates with body surface area 1, 2
Patients with creatinine clearance below 60 mL/min are at increased risk of severe bone marrow suppression, and empiric body surface area-based dosing with renal adjustment is an alternative for patients who cannot use the Calvert formula 1, 2

Formula dosing based on GFR estimates should always be used in elderly patients to provide predictable plasma carboplatin AUCs and minimize toxicity risk, as elderly patients have age-related decline in renal function that may not be reflected in serum creatinine due to decreased muscle mass 3

For carboplatin plus paclitaxel in ovarian cancer, the European Society for Medical Oncology recommends a target AUC of 5-7 mg/mL·min every 3 weeks for 6 cycles 4
For early-stage ovarian cancer, consider 3 cycles of carboplatin AUC 5-7 mg/mL·min plus paclitaxel 175 mg/m², as suggested by the European Society for Medical Oncology 4